Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 11:2021:9591177.
doi: 10.1155/2021/9591177. eCollection 2021.

Effects of High-Flux Dialysis Combined with Hemoperfusion on Serum GRP78 and miR-495-3p in Renal Failure Patients

Wei Fan  1 , Xudong Li  1 , Xiangjun Xu  1 , Hong Chu  1
Affiliations

Effects of High-Flux Dialysis Combined with Hemoperfusion on Serum GRP78 and miR-495-3p in Renal Failure Patients

Wei Fan et al. Biomed Res Int. .

Retraction in

Abstract

Objective: This study was designed to probe into the changes and clinical significance of GRP78 and miR-495-3p in renal failure (RF) patients during high-flux dialysis (HFD) combined with hemoperfusion (HP).

Methods: Sixty-five RF patients and 74 health check-ups who were admitted in our hospital from March 2015 to February 2017 were prospectively selected, and the related characteristics were retrospectively collected for analysis. GRP78 and miR-495-3p were detected in RF patients at admission (before treatment), 12 weeks after treatment (during treatment), 24 weeks after treatment (after treatment), and the control group at admission, and the relationship between the two and the occurrence, efficacy, and recurrence of RF was analyzed.

Results: Before treatment, the GRP78 mRNA level in RF patients was higher than that in health check-ups, while the miR-495-3p level was lower (P < 0.05). GRP78 mRNA in RF patients was lower than that before treatment and was the lowest after treatment. On the contrary, miR-495-3p was higher than that before treatment and was the highest after treatment (P < 0.05). The two had a significant effect on predicting RF before treatment, efficacy of patients, and their recurrence after treatment (all P < 0.001).

Conclusion: GRP78 decreased during the treatment of high-flux hemodialysis (HF-HD) combined with systemic HP in RF patients, while miR-495-3p increased. Both of them have a good reference value for RF occurrence, treatment results, and recurrence.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Expression of GRP78 and miR-495-3p before treatment. (a) GRP78 mRNA level in RF patients and health check-ups before treatment. (b) miR-495-3p level of RF patients and health check-ups before treatment. (#P < 0.05).
Figure 2
Figure 2
ROC curve of GRP78 and miR-495-3p predicting RF before treatment GRP78-AUC: 0.7983, 95% CI: 0.7183 to 0.8784 and miR-495-3p-AUC: 0.8045, 95% CI: 0.7315 to 0.8774.
Figure 3
Figure 3
Changes of GRP78 and miR-495-3p during treatment. (a) Changes of GRP78 mRNA level during treatment; (b) changes of miR-495-3p level during treatment; # means compared with before treatment (P < 0.05); @ means compared with during treatment (P < 0.05).
Figure 4
Figure 4
GRP78 and miR-495-3p are marked ROC curves in predicting the efficacy of RF patients. GRP78-AUC: 0.8656, 95% CI: 0.7691 to 0.962. miR-495-3p-AUC: 0.8286, 95% CI: 0.7033 to 0.9539.
Figure 5
Figure 5
ROC curve of GRP78 and miR-495-3p in predicting prognosis and disease recurrence in RF patients after treatment. GRP78-AUC: 0.9044, 95% CI: 0.811 to 0.9978. miR-495-3p-AUC: 0.8811, 95% CI: 0.7815 to 0.9807.
See this image and copyright information in PMC

References

    1. Tuegel C., Bansal N. Heart failure in patients with kidney disease. Heart . 2017;103(23):1848–1853. doi: 10.1136/heartjnl-2016-310794. - DOI - PubMed
    1. Ravani P., Fiocco M., Liu P., et al. Influence of mortality on estimating the risk of kidney failure in people with stage 4 CKD. Journal of the American Society of Nephrology . 2019;30(11):2219–2227. doi: 10.1681/ASN.2019060640. - DOI - PMC - PubMed
    1. Lv J. C., Zhang L. X. Prevalence and disease burden of chronic kidney disease. Advances in Experimental Medicine and Biology . 2019;1165:3–15. doi: 10.1007/978-981-13-8871-2_1. - DOI - PubMed
    1. Di Nicolò P. The dark side of the kidney in cardio-renal syndrome: renal venous hypertension and congestive kidney failure. Heart Failure Reviews . 2018;23(2):291–302. doi: 10.1007/s10741-018-9673-4. - DOI - PubMed
    1. Girndt M. Diagnostik und Therapie der chronischen Nierenerkrankung. Der Internist . 2017;58(3):243–256. doi: 10.1007/s00108-017-0195-2. - DOI - PubMed

Publication types

MeSH terms